Conclusion: A one-year course of MTX delayed and prevented RA development in high-risk UA patients. This emphasizes the importance of adequate risk prediction in trials that aim to prevent RA.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Excerpted and adapted from:
Burgers LE, Allaart CF, Huizinga TWJ, et al. Clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: Using a trial of methotrexate versus placebo in patients with undifferentiated arthritis as an example. Arthritis Rheumatol. 2017 May;69(5):926–931.